Relmada Therapeutics, Inc. RLMD Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -94%+38.3pp | -132.3%-44.8pp | -87.5%+2.6pp | -90.1%-9.9pp | |
| Liquidity | |||||
| Current ratio | 14.6×+10.2× | 4.4×-3.5× | 8×-4.3× | 12.3×-2.6× | |
| Per Share | |||||
| Book value per share | $2.19+86.1% | $1.18-58.5% | $2.84-40.2% | $4.74-60.1% | |
| Valuation | |||||
| Market capitalization | $677.17M+2,907% | $15.69M-87.4% | $124.61M+18.6% | $105.05M-83.2% | |
| Price / book | 3.1×+2.1× | 0.4×-1.0× | 1.5×+0.7× | 0.7×-2.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Relmada Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Relmada Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.